1Department of Cardiology M82, Karolinska University Hospital, Sweden.
Eur J Cardiovasc Nurs. 2013 Oct;12(5):437-45. doi: 10.1177/1474515112468067. Epub 2012 Dec 21.
Refractory angina pectoris (AP) is a persistent, painful condition characterized by angina caused by coronary insufficiency in the presence of coronary artery disease. It has been emphasized that there are possible underlying neuropathophysiological mechanisms for refractory AP but chronic ischemia is still considered to be the main problem. These patients suffer from severe AP and cannot be controlled by a combination of pharmacological therapies, angioplasty or coronary bypass surgery. AP has a negative impact on quality of life and daily life. Enhanced external counterpulsation (EECP) is a therapeutic option for these patients.
The aim of this study was to evaluate EECP after six months regarding physical capacity and health-related quality of life (HRQoL) in patients with refractory AP.
This was a study with single case research experimental design involving 34 patients treated with EECP. Six minute walk test (6MWT), functional class with Canadian Cardiological Society (CCS) classification and self-reported HRQoL questionnaires as Short Form 36 (SF-36) were collected at baseline and after treatment. CCS class and SF-36 were repeated at six months follow-up.
Patients enhanced walk distance on average by 29 m after EECP (p<0.01). CCS class also improved (p<0.001) and persisted at six months follow-up (p<0.001). HRQoL improved significantly and the effects were maintained at follow-up after the treatment.
Patients with refractory AP receive beneficial effects from EECP both in physical capacity and HRQoL. As other treatment options for this patient group are scarce, EECP should be offered to improve physical health and HRQoL in these patients.
难治性心绞痛(AP)是一种持续性、疼痛性疾病,其特征是在存在冠状动脉疾病的情况下,由于冠状动脉供血不足引起的心绞痛。已经强调了难治性 AP 可能存在潜在的神经病理生理机制,但慢性缺血仍被认为是主要问题。这些患者患有严重的 AP,不能通过药物治疗、血管成形术或冠状动脉旁路手术的联合治疗来控制。AP 对生活质量和日常生活有负面影响。增强型体外反搏(EECP)是这些患者的一种治疗选择。
本研究旨在评估难治性 AP 患者接受 EECP 治疗 6 个月后对身体能力和健康相关生活质量(HRQoL)的影响。
这是一项单病例研究的实验设计研究,涉及 34 名接受 EECP 治疗的患者。在基线和治疗后收集 6 分钟步行测试(6MWT)、加拿大心脏病学会(CCS)分类的功能分级和自我报告的 HRQoL 问卷,如短格式 36 项(SF-36)。在 6 个月的随访时,重复 CCS 分级和 SF-36。
患者接受 EECP 治疗后平均步行距离增加了 29 米(p<0.01)。CCS 分级也得到改善(p<0.001),并在 6 个月的随访时持续改善(p<0.001)。HRQoL 显著改善,治疗后随访时效果仍保持。
难治性 AP 患者接受 EECP 治疗后,身体能力和 HRQoL 均受益。由于该患者群体的其他治疗选择有限,应提供 EECP 以改善这些患者的身体健康和 HRQoL。